Is PALI or AVBP more profitable?

Palisade Bio's return on equity of -36.79% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor PALI or AVBP?

In the previous week, Palisade Bio had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for ArriVent BioPharma. Palisade Bio's average media sentiment score of 0.76 beat ArriVent BioPharma's score of 0.63 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AKTS or PALI more profitable?

Aktis Oncology's return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Palisade Bio N/A -36.79% -34.34%

Does the media prefer AKTS or PALI?

In the previous week, Aktis Oncology and Aktis Oncology both had 5 articles in the media. Palisade Bio's average media sentiment score of 0.76 beat Aktis Oncology's score of 0.66 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PALI or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Avalyn Pharma N/A N/A N/A

Does the media refer more to PALI or AVLN?

In the previous week, Palisade Bio had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Palisade Bio and 4 mentions for Avalyn Pharma. Palisade Bio's average media sentiment score of 0.76 beat Avalyn Pharma's score of 0.64 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or PALI more profitable?

Palisade Bio's return on equity of -36.79% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Palisade Bio N/A -36.79% -34.34%

Does the media prefer INBX or PALI?

In the previous week, Palisade Bio had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Palisade Bio's score of 0.76 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PALI or IMTX?

Palisade Bio has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,353.92 -$16.78M -$1.01 N/A Immatics $54.60M 22.30 -$222.26M -$1.99 N/A

Is PALI or IMTX more profitable?

Palisade Bio has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Palisade Bio's return on equity of -36.79% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Immatics -572.35% -47.36% -39.35%

Palisade Bio (PALI) Competitors

$1.95 -0.07 (-3.47%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.00 +0.05 (+2.56%)

As of 07/24/2026 07:34 PM Eastern

Compare

PALI vs. AVBP, AKTS, AVLN, INBX, and IMTX

Should you buy Palisade Bio stock or one of its competitors? MarketBeat compares Palisade Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palisade Bio include ArriVent BioPharma (AVBP), Aktis Oncology (AKTS), Avalyn Pharma (AVLN), Inhibrx Biosciences (INBX), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Palisade Bio compare to ArriVent BioPharma?

Palisade Bio (NASDAQ:PALI) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Palisade Bio has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

In the previous week, Palisade Bio had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for ArriVent BioPharma. Palisade Bio's average media sentiment score of 0.76 beat ArriVent BioPharma's score of 0.63 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Palisade Bio's return on equity of -36.79% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
ArriVent BioPharma	N/A	-48.98%	-45.44%

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Palisade Bio presently has a consensus price target of $9.00, indicating a potential upside of 361.54%. ArriVent BioPharma has a consensus price target of $44.83, indicating a potential upside of 41.30%. Given Palisade Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Palisade Bio is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Palisade Bio beats ArriVent BioPharma on 14 of the 15 factors compared between the two stocks.

How does Palisade Bio compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Palisade Bio (NASDAQ:PALI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aktis Oncology's return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Palisade Bio	N/A	-36.79%	-34.34%

Aktis Oncology currently has a consensus target price of $34.60, suggesting a potential upside of 44.83%. Palisade Bio has a consensus target price of $9.00, suggesting a potential upside of 361.54%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	196.27	-$63.73M	-$0.38	N/A
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A

In the previous week, Aktis Oncology and Aktis Oncology both had 5 articles in the media. Palisade Bio's average media sentiment score of 0.76 beat Aktis Oncology's score of 0.66 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palisade Bio beats Aktis Oncology on 8 of the 14 factors compared between the two stocks.

How does Palisade Bio compare to Avalyn Pharma?

Palisade Bio (NASDAQ:PALI) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Palisade Bio currently has a consensus price target of $9.00, indicating a potential upside of 361.54%. Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 111.09%. Given Palisade Bio's higher possible upside, equities research analysts clearly believe Palisade Bio is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Avalyn Pharma's return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has lower revenue, but higher earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

In the previous week, Palisade Bio had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Palisade Bio and 4 mentions for Avalyn Pharma. Palisade Bio's average media sentiment score of 0.76 beat Avalyn Pharma's score of 0.64 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Palisade Bio beats Avalyn Pharma on 8 of the 12 factors compared between the two stocks.

How does Palisade Bio compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Inhibrx Biosciences currently has a consensus target price of $150.00, suggesting a potential upside of 83.94%. Palisade Bio has a consensus target price of $9.00, suggesting a potential upside of 361.54%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio's return on equity of -36.79% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Palisade Bio	N/A	-36.79%	-34.34%

In the previous week, Palisade Bio had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.97 beat Palisade Bio's score of 0.76 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	920.26	-$140.05M	-$8.39	N/A
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A

Inhibrx Biosciences has a beta of 3.41, meaning that its share price is 241% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Palisade Bio beats Inhibrx Biosciences on 11 of the 16 factors compared between the two stocks.

How does Palisade Bio compare to Immatics?

Palisade Bio (NASDAQ:PALI) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

In the previous week, Palisade Bio had 4 more articles in the media than Immatics. MarketBeat recorded 5 mentions for Palisade Bio and 1 mentions for Immatics. Immatics' average media sentiment score of 1.89 beat Palisade Bio's score of 0.76 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Palisade Bio	Positive
Immatics	Very Positive

Palisade Bio currently has a consensus price target of $9.00, indicating a potential upside of 361.54%. Immatics has a consensus price target of $20.80, indicating a potential upside of 129.07%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Palisade Bio is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Palisade Bio has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Palisade Bio's return on equity of -36.79% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Immatics	-572.35%	-47.36%	-39.35%

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Palisade Bio has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A
Immatics	$54.60M	22.30	-$222.26M	-$1.99	N/A

Palisade Bio has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Immatics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Summary

Palisade Bio beats Immatics on 13 of the 17 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$338.48M	$3.67B	$7.06B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-1.93	21.29	27.14	23.62
Price / Sales	1,353.92	297.80	523.81	89.60
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	2.24	7.88	10.28	6.01
Net Income	-$16.78M	$23.86M	$3.60B	$331.99M
7 Day Performance	-1.02%	-3.82%	-1.27%	-0.63%
1 Month Performance	8.33%	-2.61%	-0.37%	-2.00%
1 Year Performance	68.10%	32.79%	18.30%	13.62%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	2.6634 of 5 stars	$1.95 -3.5%	$9.00 +361.5%	+75.7%	$338.48M	$250K	N/A	10	News Coverage Analyst Forecast
AVBP ArriVent BioPharma	2.1122 of 5 stars	$28.26 +0.1%	$44.83 +58.6%	+47.9%	$1.32B	N/A	N/A	40
AKTS Aktis Oncology	2.2495 of 5 stars	$24.63 +2.8%	$34.60 +40.5%	N/A	$1.32B	$6.50M	N/A	76	News Coverage Analyst Downgrade
AVLN Avalyn Pharma	3.8694 of 5 stars	$29.03 +1.4%	$59.00 +103.2%	N/A	$1.29B	N/A	N/A	51	News Coverage
INBX Inhibrx Biosciences	2.6624 of 5 stars	$87.61 +4.2%	$150.00 +71.2%	+253.5%	$1.29B	$1.30M	N/A	166

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. AVBP, AKTS, AVLN, INBX, and IMTX

How does Palisade Bio compare to ArriVent BioPharma?

Summary

How does Palisade Bio compare to Aktis Oncology?

Summary

How does Palisade Bio compare to Avalyn Pharma?

Summary

How does Palisade Bio compare to Inhibrx Biosciences?

Summary

How does Palisade Bio compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. AVBP, AKTS, AVLN, INBX, and IMTX

How does Palisade Bio compare to ArriVent BioPharma?

Which has more volatility & risk, PALI or AVBP?

Does the media favor PALI or AVBP?

Which has stronger earnings & valuation, PALI or AVBP?

Is PALI or AVBP more profitable?

Do insiders & institutionals believe in PALI or AVBP?

Do analysts prefer PALI or AVBP?

Summary

How does Palisade Bio compare to Aktis Oncology?

Do insiders and institutionals hold more shares of AKTS or PALI?

Is AKTS or PALI more profitable?

Do analysts recommend AKTS or PALI?

Which has higher valuation & earnings, AKTS or PALI?

Does the media prefer AKTS or PALI?

Summary

How does Palisade Bio compare to Avalyn Pharma?

Do analysts prefer PALI or AVLN?

Is PALI or AVLN more profitable?

Which has preferable earnings & valuation, PALI or AVLN?

Does the media refer more to PALI or AVLN?

Do institutionals and insiders have more ownership in PALI or AVLN?

Summary

How does Palisade Bio compare to Inhibrx Biosciences?

Do institutionals and insiders hold more shares of INBX or PALI?

Do analysts recommend INBX or PALI?

Is INBX or PALI more profitable?

Does the media prefer INBX or PALI?

Which has better valuation & earnings, INBX or PALI?

Which has more risk & volatility, INBX or PALI?

Summary

How does Palisade Bio compare to Immatics?

Does the media prefer PALI or IMTX?

Do analysts recommend PALI or IMTX?

Is PALI or IMTX more profitable?

Do institutionals & insiders believe in PALI or IMTX?

Which has stronger earnings & valuation, PALI or IMTX?

Which has more volatility and risk, PALI or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools